NEXENTIS TECHNOLOGIES INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) of $210.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease · last filed 2026-08-13
- NEXENTIS TECHNOLOGIES INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2026-06-30 was $188.00K.
- NEXENTIS TECHNOLOGIES INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2026-03-31 was $22.00K, a 69.01% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2025-12-31 was $795.00K.
- NEXENTIS TECHNOLOGIES INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2025-09-30 was -$119.00K.
- NEXENTIS TECHNOLOGIES INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2025 was $183.00K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $210.00K 10-Q · filed 2026-08-13 | $1.00M derived: sum of 3 quarters · filed 2026-08-13 | $886.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $22.00K 10-Q · filed 2026-05-14 | $817.00K derived: sum of 2 quarters · filed 2026-05-14 | $698.00K derived: sum of 3 quarters · filed 2026-05-14 | $134.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | $795.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $676.00K derived: sum of 2 quarters · filed 2026-03-31 | $112.00K derived: sum of 3 quarters · filed 2026-03-31 | $183.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$683.00K derived: sum of 2 quarters · filed 2025-11-13 | -$612.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$564.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$493.00K 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $71.00K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |